These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Action of epoxyeicosatrienoic acids on cellular function. Spector AA; Norris AW Am J Physiol Cell Physiol; 2007 Mar; 292(3):C996-1012. PubMed ID: 16987999 [TBL] [Abstract][Full Text] [Related]
8. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. Deng Y; Theken KN; Lee CR J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972 [TBL] [Abstract][Full Text] [Related]
10. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators. Shi Z; He Z; Wang DW Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996 [TBL] [Abstract][Full Text] [Related]
11. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Elmarakby AA Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511 [TBL] [Abstract][Full Text] [Related]
12. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA. Diani-Moore S; Ma Y; Gross SS; Rifkind AB Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719 [TBL] [Abstract][Full Text] [Related]
13. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Shahabi P; Siest G; Visvikis-siest S Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964 [TBL] [Abstract][Full Text] [Related]
14. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids. Jiang S; Han S; Wang DW Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644 [TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863 [TBL] [Abstract][Full Text] [Related]
17. Sexually dimorphic adaptation of cardiac function: roles of epoxyeicosatrienoic acid and peroxisome proliferator-activated receptors. Qin J; Le Y; Froogh G; Kandhi S; Jiang H; Luo M; Sun D; Huang A Physiol Rep; 2016 Jun; 4(12):. PubMed ID: 27354541 [TBL] [Abstract][Full Text] [Related]
18. Effects of dronedarone, amiodarone and their active metabolites on sequential metabolism of arachidonic acid to epoxyeicosatrienoic and dihydroxyeicosatrienoic acids. Karkhanis A; Tram NDT; Chan ECY Biochem Pharmacol; 2017 Dec; 146():188-198. PubMed ID: 28958841 [TBL] [Abstract][Full Text] [Related]
19. Epoxyeicosatrienoic acids and soluble epoxide hydrolase: potential therapeutic targets for inflammation and its induced carcinogenesis. Norwood S; Liao J; Hammock BD; Yang GY Am J Transl Res; 2010 Jul; 2(4):447-57. PubMed ID: 20733953 [TBL] [Abstract][Full Text] [Related]
20. Epoxyeicosatrienoic acid pathway in human health and diseases. Bellien J; Joannides R J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]